Why Hormone Changes Are Common and Why You Should Talk About It Like Drew Barrymore

What Counts as a "Normal" Hormone Change in Women

Hormone fluctuation is not a disease. It is an expected feature of female biology that begins at puberty and continues through postmenopause. The ovaries produce estradiol (the most biologically active form of estrogen) in a cyclic pattern during the reproductive years, with levels peaking near ovulation and dropping sharply before menstruation. That monthly swing alone can be 10-fold or greater, and most women experience its effects, including mood shifts, breast tenderness, and bloating, as routine.

The larger transitions, perimenopause, menopause, and postmenopause, represent a longer-term decline in estradiol and progesterone that the body must adapt to over years, not weeks.

The Three Main Hormonal Phases

Perimenopause typically starts in the mid-to-late 40s but can begin as early as 38 in some women. Ovarian follicle reserves fall, FSH (follicle-stimulating hormone) rises to compensate, and estradiol becomes erratic rather than steadily low. This erratic pattern is what drives many of the most new early symptoms, including irregular cycles, sleep disruption, and mood instability.

Menopause is defined clinically as 12 consecutive months without a menstrual period. The average age in the United States is 51.4 years. At that point, serum estradiol has typically fallen from a mid-cycle peak of 200 to 400 pg/mL down to postmenopausal levels below 20 pg/mL.

Postmenopause refers to every year after that 12-month mark. Estrogen does not drop to zero, because adipose tissue and the adrenal glands continue making small amounts, but the ovarian contribution is gone. Bone density loss, cardiovascular risk changes, and genitourinary atrophy are the primary long-term concerns in this phase.

Why Hormone Change Feels So Different for Each Woman

Genetic variation in estrogen receptor sensitivity, body composition, stress, sleep quality, and baseline cardiovascular health all modulate symptom severity. The Study of Women's Health Across the Nation (SWAN), which followed 3,302 women over more than two decades, found that Black women reported more frequent and more severe hot flashes than white women, and that symptom duration varied from under one year to more than 14 years [1]. That spread matters clinically: a woman who suffers 14 years of vasomotor symptoms needs a different care plan than one whose symptoms resolve in 18 months.

The Real Numbers Behind Menopausal Symptoms

The symptom burden of the menopause transition is frequently minimized in clinical encounters. A 2021 survey published in Menopause found that 73% of women did not seek treatment for their symptoms, citing embarrassment or a belief that suffering was simply expected [2]. The numbers tell a different story.

Vasomotor Symptoms

The SWAN study (N=3,302) established that the median total duration of frequent vasomotor symptoms was 7.4 years, with symptoms beginning before the final menstrual period in most participants [1]. Women who entered the transition earlier in life had the longest total duration. Night sweats disrupt sleep architecture by fragmenting REM sleep, and a 2017 study in Sleep Medicine found that women with moderate-to-severe night sweats scored 4.2 points lower on the Pittsburgh Sleep Quality Index compared to asymptomatic peers, a clinically meaningful difference [3].

Mood and Cognitive Symptoms

Estrogen interacts with serotonergic and dopaminergic pathways. The Penn Ovarian Aging Study (N=436) showed that women were 2.5 times more likely to meet criteria for a major depressive episode during perimenopause than during premenopause, even after controlling for prior depression history [4]. Brain fog, difficulty concentrating, and word-finding problems are reported by up to 44% of perimenopausal women in clinical samples.

Genitourinary Syndrome of Menopause

At least 50% of postmenopausal women develop genitourinary syndrome of menopause (GSM), formerly called vulvovaginal atrophy. Unlike hot flashes, GSM does not typically improve with time. Without treatment, symptoms of vaginal dryness, dyspareunia, and urinary urgency worsen progressively. The 2023 Menopause Society Position Statement notes that GSM "is under-reported and under-treated" and that vaginal estrogen carries a low systemic absorption profile appropriate for use even in women with contraindications to systemic hormone therapy [5].

Why Women Stay Silent About Hormonal Symptoms

Silence is not passive. It is actively reinforced by cultural norms, clinical time constraints, and decades of post-WHI fear messaging.

The WHI Shadow

The Women's Health Initiative, published in JAMA in 2002, reported a slight increase in breast cancer risk with combined conjugated equine estrogen plus medroxyprogesterone acetate (CEE/MPA) [6]. The media coverage was dramatic. Hormone therapy prescriptions fell by more than 50% within two years, and many women stopped therapy abruptly. What the headlines missed: the absolute risk increase was 8 additional breast cancer cases per 10,000 women per year, a small absolute number in women who were, on average, 63 years old and 12 years past menopause at enrollment. The WHI was not designed to study symptomatic perimenopausal women in their late 40s.

Two decades of re-analysis have substantially revised the picture. A 2019 Lancet meta-analysis (N=108,647) did confirm a modest breast cancer signal with combined HRT, but the estrogen-only arm of WHI showed a statistically significant reduction in breast cancer risk in hysterectomized women [7].

The Appointment Problem

The average primary-care visit runs 18 minutes. Bringing up hot flashes, brain fog, irregular periods, and mood changes in that window is genuinely difficult, especially when a woman also has a blood pressure check and a prescription renewal on the agenda. A 2022 study in the Journal of General Internal Medicine found that menopause was discussed in only 15% of primary-care visits by women aged 45 to 55, despite 67% of those women reporting at least one moderate-to-severe symptom in the prior month [8].

Generational Messaging

Many women were raised to treat menopause as an ending, a taboo, or a private humiliation. That messaging has a real clinical cost. Women who believe their symptoms are normal but untreatable wait an average of 2 to 3 years before seeking care, allowing preventable bone loss, sleep deprivation, and mood disorders to accumulate.

Drew Barrymore, Celebrity Candor, and the Case for Public Hormone Conversations

In 2023, Drew Barrymore disclosed on her television talk show that she was experiencing perimenopause symptoms, including hot flashes that she described as feeling like "lava." The disclosure was unscripted. It reached an estimated daytime audience of over 2 million viewers and generated significant social media discussion. Google Trends data from that week showed a 34% spike in searches for "perimenopause symptoms" in the United States.

That spike matters clinically. Search behavior predicts clinic visits. Women who search for perimenopause are more likely to raise the topic with a provider, and women who raise the topic are more likely to receive evidence-based care.

Barrymore is not the first public figure to discuss hormonal health openly. Oprah Winfrey wrote about her menopause experience in O Magazine in 2009, specifically calling out the inadequacy of her medical care. Michelle Obama discussed menopause in her podcast in 2023. Davina McCall's 2021 UK documentary on menopause is credited with a measurable increase in HRT prescriptions in England. Each of these moments demonstrates a consistent pattern: when a trusted public voice normalizes the conversation, women seek care faster.

The clinical literature supports this mechanism. A 2020 paper in Patient Education and Counseling found that women who reported having at least one open conversation about menopause with a peer or family member before their first clinical menopause visit received a diagnosis 14 months sooner than women who had no prior conversations [9].

What Barrymore Got Right

She named her symptoms specifically. She did not say she felt "off" or "tired." She described a physical sensation (lava-like heat), a timing pattern (mid-show, without warning), and an emotional impact (disorientation). That specificity is exactly what clinicians need and rarely get in a short appointment.

She normalized uncertainty. She admitted she was still figuring out what was happening to her body. That admission gives permission to other women to arrive at their doctor's office without a complete self-diagnosis.

She tied physical symptoms to mental health. She connected the hot flashes to disrupted sleep and mood changes, which reflects the actual biology accurately.

What the Current Evidence Says About Hormone Therapy

The 2023 Menopause Society Position Statement is the current U.S. Clinical standard. It states: "For women aged younger than 60 years or within 10 years of menopause onset and without contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss" [5].

Systemic HRT Options

Estrogen-only therapy is appropriate for women who have had a hysterectomy. The most studied formulations include oral conjugated equine estrogens (CEE 0.3 to 0.625 mg/day) and transdermal estradiol patches (0.025 to 0.1 mg/day). Transdermal delivery avoids first-pass hepatic metabolism, which may reduce VTE risk compared to oral formulations, a finding supported by a 2016 BMJ study (N=80,396) that found no elevated VTE risk with transdermal estradiol at standard doses [10].

Combined estrogen-progesterone therapy is used in women with an intact uterus to protect the endometrium. Micronized progesterone (Prometrium 200 mg/day for 12 days/month or 100 mg/day continuously) has a more favorable cardiovascular and breast safety profile in observational data than synthetic progestins like medroxyprogesterone acetate.

Duration is individualized. The Menopause Society does not recommend a fixed maximum duration for healthy women below 60. Annual benefit-risk reassessment with a clinician is the standard.

Non-Hormonal Options

For women with contraindications to estrogen, several non-hormonal options have FDA clearance or strong clinical evidence.

• Fezolinetant (Veozah), a neurokinin 3 receptor antagonist, received FDA approval in May 2023. In the SKYLIGHT-1 trial (N=501), it reduced moderate-to-severe hot flash frequency by 59% at 12 weeks versus 40% placebo [11].
• SSRIs and SNRIs: paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal drug for vasomotor symptoms, though escitalopram and venlafaxine also show meaningful symptom reduction in randomized trials.
• Cognitive behavioral therapy (CBT) reduced hot flash problem rating scores by 50% in the MENOS-1 RCT (N=96) [12].

Bone Protection

Estrogen therapy prevents postmenopausal bone loss. Women who begin HRT within five years of menopause onset show significantly lower rates of vertebral and hip fracture in long-term follow-up. A 2022 meta-analysis in JBMR (N=23,494 women across 57 trials) confirmed that estrogen-containing HRT reduced hip fracture risk by approximately 28% [13].

How to Have the Conversation With Your Clinician

Getting good care starts before the appointment.

Preparing for Your Visit

Track symptoms for at least two weeks before the visit. Record hot flash frequency (per day), sleep disruption (awakenings per night), mood patterns, and cycle irregularity. Apps like Clue or a simple paper log both work. Arriving with a symptom log converts a vague complaint into a clinical dataset that a provider can act on.

Ask specifically about hormone levels if you are 40 or older with new symptoms. A reasonable baseline panel includes serum FSH, estradiol (day 3 of cycle if still cycling), TSH (to rule out thyroid dysfunction), and a complete metabolic panel. Note that a single FSH or estradiol result is not diagnostic of menopause status in perimenopausal women because levels fluctuate widely day to day.

State your goals clearly. "I want to sleep through the night" is a different treatment target than "I want to stop hot flashes completely" or "I want to protect my bone density for the long term."

What to Say If You Feel Dismissed

If a provider responds to your symptom description with "that's just normal aging," you can reference the 2023 Menopause Society guidelines by name and ask whether your symptoms meet the criteria for treatment. The Menopause Society maintains a "Menopause Practitioner Locator" on its website for patients who need a specialist referral.

The Broader Public Health Case for Open Hormone Conversations

Silence about menopause has downstream costs that extend beyond individual women. Untreated vasomotor symptoms are associated with a 30% reduction in work productivity in a 2015 study published in Menopause (N=887) [14]. Sleep deprivation from night sweats increases cardiovascular risk and impairs glucose regulation. Bone loss that begins silently in perimenopause contributes to the 1.5 million osteoporotic fractures that occur annually in the United States.

The Menopause Society has noted that "the medicalization of menopause has paradoxically made it harder for women to access care," because framing menopause as a disorder to be treated, rather than a transition to be managed, created a stigma that keeps women from raising the subject [5].

The counter-framing, used by Barrymore and others, treats hormone changes as a fact of female biology deserving the same clinical attention as any other phase of life. Puberty gets school health curricula, OB-GYN visits, and pharmacies stocked with period products. The menopause transition deserves equivalent clinical infrastructure.

A 2023 editorial in JAMA Internal Medicine put it plainly: "Menopause care has been an afterthought in U.S. Medical training. Most internal medicine residents receive fewer than two hours of formal menopause education during their entire residency" [15].

Two hours. For a transition that will affect every woman who lives past her late 40s and that spans a median of 7.4 symptomatic years.